Cargando…

Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function

Plasmodium vivax exhibits dormant liver-stage parasites, called hypnozoites, which can cause relapse of malaria. The only drug currently used for eliminating hypnozoites is primaquine. The antimalarial properties of primaquine are dependent on the production of oxidized metabolites by the cytochrome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Sungim, Choi, Heun, Park, Seong Yeon, Kwak, Yee Gyung, Song, Je Eun, Shin, So Youn, Baek, Ji Hyeon, Shin, Hyun-IL, Oh, Hong Sang, Kim, Yong Chan, Yeom, Joon-Sup, Han, Jin-Hee, Kim, Min Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Parasitology and Tropical Medicine 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898651/ https://www.ncbi.nlm.nih.gov/pubmed/35247953 http://dx.doi.org/10.3347/kjp.2022.60.1.39

Ejemplares similares

Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients
por: Choi, Sungim, et al.
Publicado: (2022)

Plasmodium vivax Malaria Relapses after Primaquine Prophylaxis
por: Reddy, Pavani, et al.
Publicado: (2006)

Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function
por: Martin Ramírez, Alexandra, et al.
Publicado: (2020)

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Llanos-Cuentas, A., et al.
Publicado: (2019)

Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Watson, James A., et al.
Publicado: (2022)

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment
por: Sortica, Vinicius A, et al.
Publicado: (2016)

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
por: Baird, J. Kevin, et al.
Publicado: (2018)

The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea
por: Ingram, R Joan H, et al.
Publicado: (2014)

Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal
por: Rijal, Komal Raj, et al.
Publicado: (2019)

Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
por: Milligan, Rachael, et al.
Publicado: (2019)

Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area
por: Wångdahl, Andreas, et al.
Publicado: (2021)

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria
por: Baird, J. Kevin, et al.
Publicado: (2018)

Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study
por: Townell, Nicola, et al.
Publicado: (2012)

Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses
por: Silvino, Ana Carolina Rios, et al.
Publicado: (2016)

Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax
por: Rajgor, D. D., et al.
Publicado: (2014)

Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine
por: Chamnanphon, Monpat, et al.
Publicado: (2020)

Population Pharmacokinetics of Primaquine in the Korean Population
por: Lee, Woo-Yul, et al.
Publicado: (2021)

Correction: Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses
por: Silvino, Ana Carolina Rios, et al.
Publicado: (2018)

Parasitemia Characteristics of Plasmodium vivax Malaria Patients in the Republic of Korea
por: Huh, Ae-Jung, et al.
Publicado: (2011)

Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency
por: Kheng, Sim, et al.
Publicado: (2015)

Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia
por: Setyadi, Agus, et al.
Publicado: (2019)

Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei
por: Milner, Erin E., et al.
Publicado: (2016)

Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
por: Douglas, Nicholas M., et al.
Publicado: (2017)

Primaquine radical cure of Plasmodium vivax: a critical review of the literature
por: John, George K, et al.
Publicado: (2012)

Genetic Analysis of Primaquine Tolerance in a Patient with Relapsing Vivax Malaria
por: Bright, A. Taylor, et al.
Publicado: (2013)

Modelling the impact of rapid diagnostic tests on Plasmodium vivax malaria in South Korea: a cost–benefit analysis
por: Kim, Jung Ho, et al.
Publicado: (2021)

Failure of Supervised Chloroquine and Primaquine Regimen for the Treatment of Plasmodium vivax in the Peruvian Amazon
por: Graf, Paul C. F., et al.
Publicado: (2012)

Therapeutic efficacy of chloroquine and primaquine for Plasmodium vivax malaria treatment in southeast Iran
por: Heidari, Aliehsan, et al.
Publicado: (2012)

Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India
por: Anvikar, Anupkumar R., et al.
Publicado: (2022)

Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis
por: Zuluaga-Idarraga, Lina Marcela, et al.
Publicado: (2015)

Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study
por: Pareek, Anil, et al.
Publicado: (2015)

Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria
por: Chu, Cindy S, et al.
Publicado: (2018)

Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum
por: Wampfler, Rahel, et al.
Publicado: (2017)

Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
por: Popovici, Jean, et al.
Publicado: (2021)

Cost-Benefit Analysis of Tafenoquine for Radical Cure of Plasmodium vivax Malaria in Korea
por: Suh, Jiyeon, et al.
Publicado: (2022)

A Randomised Trial of an Eight-Week, Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan
por: Leslie, Toby, et al.
Publicado: (2008)

Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria
por: Taylor, Walter R. J., et al.
Publicado: (2021)

Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria
por: Baird, Kevin
Publicado: (2015)

The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR
por: Phommasone, Koukeo, et al.
Publicado: (2020)

Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases
por: de Pina-Costa, Anielle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jv23sfh57n52984gqpktod6ije